MedTrace Logo

Multiple Myeloma Molecular Monitoring Study

NCT03421132 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2025-06-29

No results posted yet for this study

Summary

The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment. The main hypothesis is that these tests will allow clinicians to better diagnose and manage multiple myeloma, improving patients' quality of life overall.

Conditions

Sponsors & Collaborators

  • Horizon Health Network

    lead OTHER

Principal Investigators

  • Anthony J Reiman, MD · Horizon Health Network

Eligibility

Min Age
19 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-20
Primary Completion
2024-12-31
Completion
2026-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03421132 on ClinicalTrials.gov